Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 43.94
ARQL's Cash to Debt is ranked higher than
72% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. ARQL: 43.94 )
ARQL' s 10-Year Cash to Debt Range
Min: 2.7   Max: No Debt
Current: 43.94

Equity to Asset 0.62
ARQL's Equity to Asset is ranked higher than
68% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ARQL: 0.62 )
ARQL' s 10-Year Equity to Asset Range
Min: -0.16   Max: 0.9
Current: 0.62

-0.16
0.9
F-Score: 1
Z-Score: -4.09
M-Score: -2.98
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -157.89
ARQL's Operating margin (%) is ranked higher than
65% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. ARQL: -157.89 )
ARQL' s 10-Year Operating margin (%) Range
Min: -790.25   Max: 4.14
Current: -157.89

-790.25
4.14
Net-margin (%) -154.58
ARQL's Net-margin (%) is ranked higher than
64% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. ARQL: -154.58 )
ARQL' s 10-Year Net-margin (%) Range
Min: -582.35   Max: 7.66
Current: -154.58

-582.35
7.66
ROE (%) -40.58
ARQL's ROE (%) is ranked higher than
63% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -21.87 vs. ARQL: -40.58 )
ARQL' s 10-Year ROE (%) Range
Min: -313.27   Max: 3.2
Current: -40.58

-313.27
3.2
ROA (%) -25.06
ARQL's ROA (%) is ranked higher than
68% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. ARQL: -25.06 )
ARQL' s 10-Year ROA (%) Range
Min: -53.68   Max: 2.58
Current: -25.06

-53.68
2.58
ROC (Joel Greenblatt) (%) -2227.57
ARQL's ROC (Joel Greenblatt) (%) is ranked higher than
58% of the 872 Companies
in the Global Biotechnology industry.

( Industry Median: -196.35 vs. ARQL: -2227.57 )
ARQL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2227.57   Max: 6.18
Current: -2227.57

-2227.57
6.18
Revenue Growth (%) -27.60
ARQL's Revenue Growth (%) is ranked higher than
62% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -1.30 vs. ARQL: -27.60 )
ARQL' s 10-Year Revenue Growth (%) Range
Min: -61.3   Max: 44.2
Current: -27.6

-61.3
44.2
EBITDA Growth (%) -16.40
ARQL's EBITDA Growth (%) is ranked higher than
69% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.30 vs. ARQL: -16.40 )
ARQL' s 10-Year EBITDA Growth (%) Range
Min: -45.5   Max: 143.8
Current: -16.4

-45.5
143.8
EPS Growth (%) -16.90
ARQL's EPS Growth (%) is ranked higher than
71% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.80 vs. ARQL: -16.90 )
ARQL' s 10-Year EPS Growth (%) Range
Min: -48.4   Max: 132.1
Current: -16.9

-48.4
132.1
» ARQL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

ARQL Guru Trades in Q1 2013

Jim Simons 378,278 sh (+118.99%)
Jean-Marie Eveillard 4,539,651 sh (unchged)
» More
Q2 2013

ARQL Guru Trades in Q2 2013

Jim Simons 574,282 sh (+51.81%)
Jean-Marie Eveillard 4,507,558 sh (-0.71%)
» More
Q3 2013

ARQL Guru Trades in Q3 2013

Chuck Royce 60,000 sh (New)
Jean-Marie Eveillard 3,314,553 sh (-26.47%)
Jim Simons 221,183 sh (-61.49%)
» More
Q4 2013

ARQL Guru Trades in Q4 2013

Paul Tudor Jones 17,323 sh (New)
Chuck Royce 160,000 sh (+166.67%)
Jean-Marie Eveillard 2,843,599 sh (-14.21%)
Jim Simons 80,638 sh (-63.54%)
» More
» Details

Insider Trades

Latest Guru Trades with ARQL

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2013-09-30 Reduce -26.47%0.01%$2.15 - $2.79 $ 1.66-34%3314553
Jean-Marie Eveillard 2012-12-31 Add 49.46%0.01%$2.18 - $2.95 $ 1.66-36%4539651
Jean-Marie Eveillard 2012-06-30 Add 28.79%0.01%$5.53 - $8.16 $ 1.66-75%2673589
George Soros 2011-12-31 Sold Out 0.0014%$4.58 - $6.05 $ 1.66-70%0
George Soros 2011-09-30 Add 54.79%$4.11 - $6.64 $ 1.66-68%16100
Jean-Marie Eveillard 2011-03-31 Add 84.22%0.03%$5.85 - $6.95 $ 1.66-74%1693456
George Soros 2011-03-31 New Buy$5.85 - $6.95 $ 1.66-74%12200
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.70
ARQL's P/B is ranked higher than
87% of the 791 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. ARQL: 1.70 )
ARQL' s 10-Year P/B Range
Min: 0.9   Max: 111.17
Current: 1.7

0.9
111.17
P/S 6.50
ARQL's P/S is ranked higher than
64% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 10.27 vs. ARQL: 6.50 )
ARQL' s 10-Year P/S Range
Min: 1.3   Max: 102.75
Current: 6.5

1.3
102.75
EV-to-EBIT 250.00
ARQL's EV-to-EBIT is ranked lower than
84% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. ARQL: 250.00 )
ARQL' s 10-Year EV-to-EBIT Range
Min: 102.5   Max: 223.1
Current: 250

102.5
223.1

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.80
ARQL's Price/Net Cash is ranked higher than
87% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. ARQL: 2.80 )
ARQL' s 10-Year Price/Net Cash Range
Min: 1.91   Max: 52.13
Current: 2.8

1.91
52.13
Price/Net Current Asset Value 2.80
ARQL's Price/Net Current Asset Value is ranked higher than
88% of the 525 Companies
in the Global Biotechnology industry.

( Industry Median: 9.60 vs. ARQL: 2.80 )
ARQL' s 10-Year Price/Net Current Asset Value Range
Min: 1.89   Max: 113.89
Current: 2.8

1.89
113.89
Price/Tangible Book 1.70
ARQL's Price/Tangible Book is ranked higher than
89% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. ARQL: 1.70 )
ARQL' s 10-Year Price/Tangible Book Range
Min: 0.69   Max: 14.19
Current: 1.7

0.69
14.19
Price/Median PS Value 0.70
ARQL's Price/Median PS Value is ranked higher than
79% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. ARQL: 0.70 )
ARQL' s 10-Year Price/Median PS Value Range
Min: 0.12   Max: 3.64
Current: 0.7

0.12
3.64
Earnings Yield (Greenblatt) 0.40
ARQL's Earnings Yield (Greenblatt) is ranked lower than
73% of the 378 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. ARQL: 0.40 )
ARQL' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 1
Current: 0.4

0.4
1
Forward Rate of Return (Yacktman) -55.89
ARQL's Forward Rate of Return (Yacktman) is ranked higher than
60% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. ARQL: -55.89 )
ARQL' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -38.6   Max: -6.1
Current: -55.89

-38.6
-6.1

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AQL.Germany
ArQule, Inc. was incorporated in Delaware. The Company is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. It employ technologies such as its ArQule Kinase Inhibitor Platform ('AKIP') to design and develop drugs that have the potential to fulfill this mission. Its product candidates and programs span a continuum of research and development ranging from drug discovery to advanced clinical testing. Its product candidate is tivantinib (ARQ 197), an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase. C-Met is a promising target for cancer therapy, based on its multiple roles in cancerous cell proliferation, tumor spread, new blood vessel formation and resistance to certain drug therapies. The Company and its partners, Daiichi Sankyo Co., Ltd. ('Daiichi Sankyo') and Kyowa Hakko Kirin Co., Ltd. ('Kyowa Hakko Kirin'), are implementing a clinical development program designed to realize the broad potential of tivantinib as a well-tolerated single agent and in combination with other anti-cancer therapies in a number of disease indications The Company has licensed commercial rights to tivantinib for human cancer indications to Daiichi Sankyo in the U.S., Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where it has licensed commercial rights to Kyowa Hakko Kirin. Its proprietary pipeline is directed toward molecular targets and biological processes with demonstrated roles in the development of human cancers. The advanced candidates in this pipeline are ARQ 087, an inhibitor of fibroblast growth factor receptor, ARQ 621, an inhibitor of the Eg5 kinesin motor protein, and ARQ 736, an inhibitor of the RAF kinases, all of which are in Phase 1 clinical testing. Its drug discovery efforts are engaged mainly on AKIP, which it is using to generate compounds designed to inhibit kinases without competing with adenosine triphosphate ('ATP') for binding to the target kinase, as well as other types of kinase inhibitors. ATP is a chemical found in all living cells and is the energy source involved in a variety of physiological processes. The Company faces competition from pharmaceutical companies, biotechnology companies and academic and research organizations. The Company's product candidates, as well as the activities associated with their research, development and commercialization, are subject to extensive regulation by the FDA in the United States and by comparable authorities in other countries.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide